100 related articles for article (PubMed ID: 22980722)
1. Recombinant FVIIa concentrate-associated thrombotic events in congenital bleeding disorders other than hemophilias.
Girolami A; de Marinis GB; Bonamigo E; Lombardi AM
Hematology; 2012 Nov; 17(6):346-9. PubMed ID: 22980722
[TBL] [Abstract][Full Text] [Related]
2. Discrepant ratios of arterial vs. venous thrombosis in hemophilias A and B as compared to FVII deficiency.
Girolami A; Berti de Marinis G; Bertozzi I; Peroni E; Tasinato V; Lombardi AM
Eur J Haematol; 2013 Aug; 91(2):152-6. PubMed ID: 23621110
[TBL] [Abstract][Full Text] [Related]
3. Safety update on the use of recombinant activated factor VII in approved indications.
Neufeld EJ; Négrier C; Arkhammar P; Benchikh el Fegoun S; Simonsen MD; Rosholm A; Seremetis S
Blood Rev; 2015 Jun; 29 Suppl 1():S34-41. PubMed ID: 26073367
[TBL] [Abstract][Full Text] [Related]
4. Recombinant activated factor VII as a universal haemostatic agent.
Hedner U
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S147-52. PubMed ID: 9819047
[TBL] [Abstract][Full Text] [Related]
5. Use of recombinant factor VIIa in hereditary bleeding disorders.
Poon MC
Curr Opin Hematol; 2001 Sep; 8(5):312-8. PubMed ID: 11604567
[TBL] [Abstract][Full Text] [Related]
6. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
[TBL] [Abstract][Full Text] [Related]
7. Use and Future Investigations of Recombinant and Plasma-Derived Coagulation and Anticoagulant Products in the Neonate.
Punzalan RC; Gottschall JL
Transfus Med Rev; 2016 Oct; 30(4):189-96. PubMed ID: 27576087
[TBL] [Abstract][Full Text] [Related]
8. Thrombosis in rare bleeding disorders.
Ruiz-Sáez A
Hematology; 2012 Apr; 17 Suppl 1():S156-8. PubMed ID: 22507808
[TBL] [Abstract][Full Text] [Related]
9. Ischemic Strokes in Congenital Bleeding Disorders: Comparison with Myocardial Infarction and other Acute Coronary Syndromes.
Girolami A; Silvia F; Elisabetta C; Edoardo P; Bruno G
Cardiovasc Hematol Disord Drug Targets; 2016; 16(1):6-12. PubMed ID: 27305946
[TBL] [Abstract][Full Text] [Related]
10. Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review.
Girolami A; Ruzzon E; Tezza F; Scandellari R; Vettore S; Girolami B
Haemophilia; 2006 Jul; 12(4):345-51. PubMed ID: 16834733
[TBL] [Abstract][Full Text] [Related]
11. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
12. Surgical procedures in patients with Glanzmann's thrombasthenia: case series and literature review.
Ganapule A; Jain P; Abubacker FN; Korula A; Abraham A; Mammen J; George B; Mathews V; Srivastava A; Viswabandya A
Blood Coagul Fibrinolysis; 2017 Mar; 28(2):171-175. PubMed ID: 27273143
[TBL] [Abstract][Full Text] [Related]
13. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
[TBL] [Abstract][Full Text] [Related]
14. The spectrum of inherited bleeding disorders in pediatrics.
El-Bostany EA; Omer N; Salama EE; El-Ghoroury EA; Al-Jaouni SK
Blood Coagul Fibrinolysis; 2008 Dec; 19(8):771-5. PubMed ID: 19002043
[TBL] [Abstract][Full Text] [Related]
15. Invited commentary.
Shander A; Javidroozi M
Ann Thorac Surg; 2010 Feb; 89(2):576-7. PubMed ID: 20103345
[No Abstract] [Full Text] [Related]
16. Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery.
Riddell A; Abdul-Kadir R; Pollard D; Tuddenham E; Gomez K
Thromb Haemost; 2011 Sep; 106(3):521-7. PubMed ID: 21833443
[TBL] [Abstract][Full Text] [Related]
17. Off-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study.
Witmer CM; Huang YS; Lynch K; Raffini LJ; Shah SS
J Pediatr; 2011 May; 158(5):820-825.e1. PubMed ID: 21146180
[TBL] [Abstract][Full Text] [Related]
18. Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation.
Mariani G; Napolitano M; Dolce A; Pérez Garrido R; Batorova A; Karimi M; Platokouki H; Auerswald G; Bertrand AM; Di Minno G; Schved JF; Bjerre J; Ingerslev J; Sørensen B; Ruiz-Saez A; ;
Thromb Haemost; 2013 Feb; 109(2):238-47. PubMed ID: 23238632
[TBL] [Abstract][Full Text] [Related]
19. Off-label use of recombinant activated coagulation factor VII for bleeding may raise the risk of arterial thrombosis.
Ferrari L; Podda GM
Intern Emerg Med; 2011 Jun; 6(3):261-2. PubMed ID: 21541718
[No Abstract] [Full Text] [Related]
20. Thrombosis associated with the use of recombinant activated factor VII: profiling two events.
Ng HJ; Loh SM; Tan DC; Lee LH
Thromb Haemost; 2004 Dec; 92(6):1448-9. PubMed ID: 15624250
[No Abstract] [Full Text] [Related]
[Next] [New Search]
